{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Switzerland Healthcare news", "home_page_url": "https://sharemaestro.com/newsreel/ch/healthcare/", "feed_url": "https://sharemaestro.com/newsreel/ch/healthcare/feed.json", "description": "Latest Healthcare company headlines from Switzerland, newest first, with industry sections, source links and company research.", "language": "en", "items": [{"id": "source:feb4c10773207b089470a45f64ed6c862c294f24a43dcb044c603c039d23c4d0", "url": "https://finance.yahoo.com/m/c7509af1-9542-320b-b10c-f73523ccdd58/eli-lilly-stock-nears-buy.html", "external_url": "https://finance.yahoo.com/m/c7509af1-9542-320b-b10c-f73523ccdd58/eli-lilly-stock-nears-buy.html", "title": "Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains", "content_text": "While Eli Lilly isn't a perfect technical setup, it's still a fundamental powerhouse that could be worth considering. Continue Reading", "date_published": "2026-08-14T12:00:27+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "LLY"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/2a75d284-1006-47a9-95a6-1b68449f2df1/"}]}}, {"id": "source:c3a98a5f8747a521982b0d128ec0396d98d710f52be0af746179603a914f830a", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "title": "Johnson & Johnson (JNJ)\u2019s $5.5B Talc Settlement: Turning Point or Temporary Relief?", "content_text": "The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging population is fueling demand for healthcare. US healthcare spending is forecast to hit $6 trillion in 2026 from $5.7 trillion in 2025. This trend reflects an expanding market for medical products companies. Yet for large healthcare companies, legal issues can erode the benefits of favorable mark", "date_published": "2026-08-13T23:07:26+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "JOHNSON&JOHNSON", "sentiment_url": "https://sharemaestro.com/sentiment/64c0807a-7d61-415c-b23f-0e2f1970f21f/"}]}}, {"id": "source:77b6b88f9dfa98351eaeec97554088f931f18810cc1e32a2b54d8b3b9e8be6b4", "url": "https://finance.yahoo.com/healthcare/articles/could-alcon-alc-rxsight-rxst-224910777.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-alcon-alc-rxsight-rxst-224910777.html", "title": "Could Alcon (ALC) and RxSight (RXST)\u2019s Partnership Reshape the Future of Cataract Surgery?", "content_text": "Two ophthalmic technology leaders, Alcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST), earlier on July 6 entered into a strategic collaboration that highlights the evolving landscape of cataract and refractive surgery. The companies announced a non-exclusive pact to co-develop post-operatively adjustable pseudophakic intraocular lenses (PCIOLs). By pairing RxSight's proprietary light-adjustable technology, which allows eye surgeons to fine-tune a patient's vision using UV light after surgery, with Alcon's global commercial footprint and surgical equipment portfolio, the agreement validates ", "date_published": "2026-08-13T22:49:10+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:3bef01e419d9d389253447d91603c1c8fa9617bbef41a880e7bc6b80a5efa330", "url": "https://finance.yahoo.com/markets/stocks/articles/why-netflix-stock-popped-today-192704519.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/why-netflix-stock-popped-today-192704519.html", "title": "Why Netflix Stock Popped Today", "content_text": "This article first appeared on GuruFocus. Bill Ackman (Trades, Portfolio)'s Pershing Square Capital Management has built a new position in Netflix (NASDAQ:NFLX), returning to the streaming company after a costly exit in 2022, according to a six-month financial report. Warning! GuruFocus has detected 2 Warning Sign with SNDK. Is NFLX fairly valued? Test your thesis with our free DCF calculator. Netflix stock rose 4% after the report on Thursday. The investment totals 3.15 million shares and represents 4.9% of Pershing Square's portfolio. Ackman's latest move marks a reversal from his earlier de", "date_published": "2026-08-13T19:27:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:cf0748fc59d9aceed27a4364f0e035fde029d48047637e92d900061e02d755d2", "url": "https://finance.yahoo.com/markets/stocks/articles/bill-ackman-buys-back-netflix-191039109.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/bill-ackman-buys-back-netflix-191039109.html", "title": "Bill Ackman Buys Back Into Netflix Four Years After Selling at a Loss", "content_text": "This article first appeared on GuruFocus. Bill Ackman (Trades, Portfolio) disclosed six new holdings, buying Netflix (NASDAQ:NFLX), Visa (NYSE:V), Mastercard (NYSE:MA), eye care company Alcon (NYSE:ALC), exchange operator Intercontinental Exchange (NYSE:ICE) and financial data provider S&P Global (NYSE:SPGI) from the second quarter onward. The shares sit across his funds, including Pershing Square USA (NYSE:PSUS). Pershing Square USA shares were up 1.66% on the day. Ackman said he thinks the companies' earnings are set for strong growth, which he treats as the main driver of investment value o", "date_published": "2026-08-13T19:10:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:81205c8ad0b6668993db3e0320e50ff24e7a6c619fa44ac9e8181dc6eadd6e38", "url": "https://finance.yahoo.com/healthcare/articles/lensar-q2-earnings-call-highlights-170437968.html", "external_url": "https://finance.yahoo.com/healthcare/articles/lensar-q2-earnings-call-highlights-170437968.html", "title": "LENSAR Q2 Earnings Call Highlights", "content_text": "Key Points Interested in LENSAR, Inc.? Here are five stocks we like better. LENSAR's second-quarter revenue rose 18% to $16.5 million, driven by a 20% increase in recurring revenue to $13.7 million and a 23% increase in procedure revenue. GAAP net income reached $3.5 million, while adjusted EBITDA rose to a record $3.6 million. Procedure volume increased 13% year over year to 58,682, and U.S. market share reached 24.1%. LENSAR placed 10 ALLY systems during the quarter, bringing the ALLY installed base to about 215 systems and total global installations to 445. Gross margin improved to about 59", "date_published": "2026-08-13T17:04:37+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:c05e101117320c1e95951383a2e0481aa9e8893bc9f168a3afa8158464cfc1ea", "url": "https://finance.yahoo.com/markets/stocks/articles/lensar-inc-q2-2026-earnings-170038305.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/lensar-inc-q2-2026-earnings-170038305.html", "title": "LENSAR, Inc. Q2 2026 Earnings Call Summary", "content_text": "LENSAR, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Reset and Operational Performance Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management successfully transitioned back to independent operations following the termination of the Alcon merger, focusing on rebuilding commercial momentum and long-term sustainability. Revenue growth of 18% was primarily driven by a 23% increase in procedure revenue, reflecting higher utilization of the ALLY system across the expanding installed ba", "date_published": "2026-08-13T17:00:38+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:42a629e691055a42ec13ef8bc6f0f3c3d31f7b2c7e8038507a15807a75e34ff2", "url": "https://finance.yahoo.com/healthcare/articles/market-chatter-novartis-wins-uk-153302721.html", "external_url": "https://finance.yahoo.com/healthcare/articles/market-chatter-novartis-wins-uk-153302721.html", "title": "Update: Market Chatter: Novartis Wins UK Court Challenge to Entresto Patent", "content_text": "(Updates with response from a Novartis spokesperson in the fourth and fifth paragraphs.)Novartis (NVS) defeated a bid by Accord Healthcare to invalidate its Entresto patent, with a UK court ruling that the patent and a related protection certificate remain valid, Reuters reported Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-13T15:33:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "BION"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BION", "name": "BB Biotech AG", "sentiment_url": "https://sharemaestro.com/sentiment/d5faa5b5-21aa-4183-97e6-5c9badcfcdaa/"}]}}, {"id": "source:37823f38c65907f316dcb216ce397396f279151ec7bd4b7c7cacb24fdc153929", "url": "https://finance.yahoo.com/markets/stocks/articles/pershing-square-h1-earnings-call-150609179.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/pershing-square-h1-earnings-call-150609179.html", "title": "Pershing Square H1 Earnings Call Highlights", "content_text": "Pershing Square (LON:PSH) held its first earnings call as Pershing Square Inc., with Chief Executive Officer and Chairman Bill Ackman outlining a strategy centered on long-term compounding in its existing investment vehicles, potential new fund launches and efforts to improve trading in Pershing Square USA Ltd. shares. Ackman said the firm's principal focus remains investment performance rather than frequent fundraising. He said Pershing Square expects the earnings of its portfolio companies to compound over time and believes the holdings are currently undervalued. In turn, he said, increases ", "date_published": "2026-08-13T15:06:09+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:b1ff61e161cc0acc56791a1e251cfcdf058fbfe9da2d1a4b8339eade8eab4f47", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQWVpMMWpxLXY0YlIwbTNLdnIzVlRwSHdVZkZmbzhaOUZrWm8zYldCeXpzSDdEY0ZPVDU0clJjd3N2ZG5wbDlORFltSDRmb0ZTTE5LaHo0ZmRlN1ZPdjRKVFJncTFHOURCeU83OWdlRTk2U1hya3dvOUs0eUw3S3E4b1JPajBCMjZDV2hNR0lXWDV6aU1JSUlsM2dFRGVWal9ja1dQbkJIM3RFRXRzYkFhNEhoVlJWbG1JWWZ0OWhXc2FaXzFhTDhhWjFBVjdyVDQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQWVpMMWpxLXY0YlIwbTNLdnIzVlRwSHdVZkZmbzhaOUZrWm8zYldCeXpzSDdEY0ZPVDU0clJjd3N2ZG5wbDlORFltSDRmb0ZTTE5LaHo0ZmRlN1ZPdjRKVFJncTFHOURCeU83OWdlRTk2U1hya3dvOUs0eUw3S3E4b1JPajBCMjZDV2hNR0lXWDV6aU1JSUlsM2dFRGVWal9ja1dQbkJIM3RFRXRzYkFhNEhoVlJWbG1JWWZ0OWhXc2FaXzFhTDhhWjFBVjdyVDQ?oc=5", "title": "Kuros Biosciences erzielt im ersten Halbjahr 2026 Gewinn bei 45 % Umsatzwachstum", "content_text": "Kuros Biosciences erzielt im ersten Halbjahr 2026 Gewinn bei 45 % Umsatzwachstum", "date_published": "2026-08-13T14:37:00+00:00", "authors": [{"name": "Investing.com Deutsch"}], "tags": ["Market update", "KURN"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "KURN", "name": "Kuros Biosciences AG", "sentiment_url": "https://sharemaestro.com/sentiment/d89120d8-f151-454c-9944-9284e963c961/"}]}}, {"id": "source:697a50a175a72f51f10d9ab526a32ec1d0ca376293fdd7bbf1593b0640424756", "url": "https://finance.yahoo.com/markets/stocks/articles/ackman-adds-netflix-visa-mastercard-124620613.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/ackman-adds-netflix-visa-mastercard-124620613.html", "title": "Ackman adds Netflix, Visa and Mastercard in portfolio revamp", "content_text": "Investing.com -- Bill Ackman disclosed six new portfolio holdings on Thursday, including Netflix, Visa, and Mastercard, representing his largest portfolio restructuring in several years. The billionaire investor said he began purchasing the shares during the second quarter for his investment funds, including Pershing Square USA, which started trading on the New York Stock Exchange in April. The additions also include eye care company Alcon, exchange operator Intercontinental Exchange, and financial data provider S&P Global. Netflix previously appeared in Ackman's portfolio briefly in 2022 befo", "date_published": "2026-08-13T12:46:20+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:9389fcc30edda6908b405a6308af8404cff60a62214f70368ccd9a2835f0b286", "url": "https://finance.yahoo.com/markets/stocks/articles/ackman-unveils-six-investments-including-120701203.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/ackman-unveils-six-investments-including-120701203.html", "title": "Ackman unveils six new investments including Netflix, Visa, Mastercard in biggest portfolio overhaul in years", "content_text": "By Svea Herbst-Bayliss NEW YORK, Aug 13 (Reuters) - Bill Ackman unveiled six new holdings including Netflix, Visa and Mastercard, marking the billionaire investor's biggest portfolio overhaul in years. Ackman said on Thursday he acquired shares \u200cstarting in the second quarter that will be held in his investment funds including his newest offering \u200cPershing Square USA, which was listed on the New York Stock Exchange in April. Along with Netflix, which Ackman held briefly in 2022 before selling \u200bat a loss, his funds are also investing in eye care firm Alcon, exchange operator Intercontinental Ex", "date_published": "2026-08-13T12:07:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:80871c059d165abce549a6c22b10773486eeba264f4123ddfa9b7b7e250b577d", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPcTN2eDNhWjVpWEZwdjZyZkpnYWVfYXlUU1kzZkdlWjRGeF9OQVVUZm1ndm95TGpvb0ROVEZPWkJkWENUY1ZnTTByc21jcUxqWmJvYlREdHMyYnpiTVowa0RzUEpRYzRwUDR5aGl2ZG5nVjNmZTlGaG9IdUtRR0wxNXhkUy1Dd0trTVZjVk4xNGNMSUxPaDlxVE9LMWhQbGF5ZnZaMlZuNXFKcWlnWVliVzNvaGpQUDNacVZpWWxXSTl3SDR4ZzdTcWtrczhpYkFOVHkxc0JPSFlxQmtqRk9yYjRadw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPcTN2eDNhWjVpWEZwdjZyZkpnYWVfYXlUU1kzZkdlWjRGeF9OQVVUZm1ndm95TGpvb0ROVEZPWkJkWENUY1ZnTTByc21jcUxqWmJvYlREdHMyYnpiTVowa0RzUEpRYzRwUDR5aGl2ZG5nVjNmZTlGaG9IdUtRR0wxNXhkUy1Dd0trTVZjVk4xNGNMSUxPaDlxVE9LMWhQbGF5ZnZaMlZuNXFKcWlnWVliVzNvaGpQUDNacVZpWWxXSTl3SDR4ZzdTcWtrczhpYkFOVHkxc0JPSFlxQmtqRk9yYjRadw?oc=5", "title": "Kuros Biosciences AG legt Ergebniszahlen f\u00fcr das Halbjahr bis zum 30. Juni 2026 vor", "content_text": "Kuros Biosciences AG legt Ergebniszahlen f\u00fcr das Halbjahr bis zum 30. Juni 2026 vor", "date_published": "2026-08-13T11:52:38+00:00", "authors": [{"name": "MarketScreener Schweiz"}], "tags": ["Market update", "KURN"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "KURN", "name": "Kuros Biosciences AG", "sentiment_url": "https://sharemaestro.com/sentiment/d89120d8-f151-454c-9944-9284e963c961/"}]}}, {"id": "source:173587cbd1ccaf78c08c2be14fdcba979c320ad76106d1cbb52b41d285549986", "url": "https://finance.yahoo.com/markets/stocks/articles/bill-ackmans-pershing-square-buys-115159065.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/bill-ackmans-pershing-square-buys-115159065.html", "title": "Bill Ackman's Pershing Square buys Netflix, 5 other stocks in 2026", "content_text": "Bill Ackman's Pershing Square Inc. disclosed on Wednesday that it had taken a new position in Netflix stock, returning to the streaming company after a loss-making investment in 2022, and added five other new positions in the first half of 2026. As of June 30, Pershing Square's Netflix stake totaled 3.15 million shares, equal to 4.9% of the firm's portfolio, the company said. Pershing Square CEO Bill Ackman and Chief Investment Officer Ryan Israel wrote in a second-quarter letter to investors that a market focused on artificial intelligence had created opportunities in other stocks, according ", "date_published": "2026-08-13T11:51:59+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:6e157b38c684413e78760ab1f2f0093e5cc3f1c64dd187e69900c7ad56241742", "url": "https://finance.yahoo.com/markets/stocks/articles/labcorp-holdings-lh-fully-priced-170843763.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/labcorp-holdings-lh-fully-priced-170843763.html", "title": "Is Labcorp Holdings (LH) Fully Priced Following Oncology Approvals And Raised Outlook?", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced melanoma and nationwide access to Roche's VENTANA PTEN RxDx Assay for prostate cancer. See our latest analysis for Labcorp Holdings. Labcorp Holdings has attracted more attention in recent months, with oncology diagnostics approvals and stronger earnings updates sitting alongside a 30 day share price return of 16.48% and a 1 year total shareholder return of 20.98%. Together, these factors point to building momentum from both recent news and longer term execution. If this precision medicine story has your interest, it can be a useful time to scan other healthcare focused opportunities via the 43 healthcare AI stocks After a 26.7% move over 90 days and with Labcorp Holdings now sitting only about 5% below the average analyst target and roughly 1% below intrinsic estimates, is the market still too cautious or already baking in the good news? Most Popular Narrative: 1% Undervalued The most followed narrative on Labcorp Holdings pegs fair value at about $326.81 per share, slightly above the last close of $322.42, which puts the current move into context. The analysts have a consensus price target of $326.81 for Labcorp Holdings based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $360.0, and the most bearish reporting a price target of just $270.0. Read the complete narrative. Want to see what sits behind that fair value gap for Labcorp Holdings? The narrative leans heavily on steadier revenue growth, firmer margins and a valuation multiple that shifts over time. Curious which of those inputs carries the most weight in the model. Result: Fair Value of $326.81 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, investors in Labcorp Holdings still need to watch for regulatory changes such as PAMA and pricing pressure in diagnostics, which could squeeze revenue and margins. Find out about the key risks to this Labcorp Holdings narrative. Another View On Labcorp Holdings Valuation The fair value narrative for Labcorp Holdings leans on discounted cash flows and puts the stock at about $326 per share, which is slightly above the current price of $322.42 and described as undervalued. A different lens that focuses on the current P/E ratio tells a less generous story. Story Continues On this measure, Labcorp Holdings trades on a 26.1x P/E. That is higher than both the peer average of 24.6x and the US Healthcare industry at 24.9x, and it also sits at the fair ratio of 26.1x. In practice, that suggests less room for error if earnings or growth assumptions fall short, so how comfortable are you with that pricing power? See what the numbers say about this price \u2014 find out in our valuation breakdown.NYSE:LH P/E Ratio as at Aug 2026 Next Steps Sentiment on Labcorp Holdings is mixed, with both concern and optimism in play. It helps to review the full picture and act on your own judgment using the 3 key rewards and 1 important warning sign. Looking for more investment ideas beyond Labcorp Holdings? Do not stop with Labcorp Holdings. The next step is widening your watchlist so you can compare strengths, spot fresh opportunities and avoid putting all your capital in one place. Target potential value by scanning companies that combine solid fundamentals with attractive pricing using the 49 high quality undervalued stocks. Prioritise resilience by reviewing companies that feature strong finances and prudent balance sheets through the solid balance sheet and fundamentals stocks screener (50 results). Hunt for underappreciated ideas that the market may be overlooking with the scree", "date_published": "2026-08-12T17:08:43+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ROP"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ROP", "name": "Roche Holding AG", "sentiment_url": "https://sharemaestro.com/sentiment/fdac9d6f-d683-44f3-ad28-dfbb55fe934d/"}]}}, {"id": "source:28f18b773ccaf69d248383eff739e70477d9fabb13d653ed5d20dbc99c06e7dd", "url": "https://finance.yahoo.com/healthcare/articles/lilly-targets-black-market-retatrutide-165417136.html", "external_url": "https://finance.yahoo.com/healthcare/articles/lilly-targets-black-market-retatrutide-165417136.html", "title": "Lilly Targets Black-Market Retatrutide Sellers", "content_text": "This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY fairly valued? Test your thesis with our free DCF calculator. The company filed six lawsuits against U.S. businesses it accuses of selling unapproved versions of the drug while it remains in clinical development. Retatrutide is still in Phase 3 trials for obesity, type 2 diabetes and related conditi", "date_published": "2026-08-12T16:54:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/2a75d284-1006-47a9-95a6-1b68449f2df1/"}]}}, {"id": "source:9073c5771f91b89c5e6ebe007a507f5ff605ec1bb6a0376e88f53fbdfcbb6eb0", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-advances-seltorexant-161141375.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-advances-seltorexant-161141375.html", "title": "Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid acting treatment option. The company also entered a multi year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson's focus on higher growth therapeutic and medtech areas that are important for its lo", "date_published": "2026-08-12T16:11:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "JNJ"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "JOHNSON&JOHNSON", "sentiment_url": "https://sharemaestro.com/sentiment/64c0807a-7d61-415c-b23f-0e2f1970f21f/"}]}}, {"id": "source:bf7defe4a71158af0a1bd84bf51ac804a6c1a409a21dd1ca573562c764d9813c", "url": "https://seekingalpha.com/news/4631300-lilly-files-six-lawsuits-to-crack-down-on-black-market-retatrutide-weight-loss-shots?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4631300-lilly-files-six-lawsuits-to-crack-down-on-black-market-retatrutide-weight-loss-shots?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Lilly files six lawsuits to crack down on black market retatrutide weight-loss shots", "content_text": "[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Lilly escalated its fight against black-market retatrutide by filing six new lawsuits against U.S. sellers, including compounding pharmacies, medical spas, and online vendors, the drugmaker said Wednesday in a statement [https://seekingalpha.com/pr/20616057-lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal]. The company said retatrutide remains an investigational Phase 3 molecule, and no retatrutide medicine has been approved for human use by any regulator worldwide. The FDA has made c", "date_published": "2026-08-12T09:41:38+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/2a75d284-1006-47a9-95a6-1b68449f2df1/"}]}}, {"id": "source:ea7e7c83c69cf0488590973f55b3e45a00e458be651cdf2ada60e1789a419701", "url": "https://finance.yahoo.com/technology/articles/sbo-strengthens-position-3d-metal-211539467.html", "external_url": "https://finance.yahoo.com/technology/articles/sbo-strengthens-position-3d-metal-211539467.html", "title": "SBO Strengthens Position in 3D Metal Printing: Expanded Capacity in the US and the UK, Award for 3T", "content_text": "TERNITZ, AUSTRIA - August 11, 2026 (NEWMEDIAWIRE) - SBO AG, listed on the leading index ATX of the Vienna Stock Exchange, is expanding its 3D metal printing capacity in the US and the UK and strengthening its market position in Europe through an award for its subsidiary 3T. Both steps advance SBO's diversification strategy in the growing additive manufacturing market. In the US, SBO has expanded additive manufacturing capacity by adding one VELO XC and two Renishaw 500Q printers for high-performance alloys Inconel and Titanium in Q2 2026. In addition, two more VELO XC printers have been ordere", "date_published": "2026-08-11T21:15:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TECN"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TECN", "name": "Tecan Group AG", "sentiment_url": "https://sharemaestro.com/sentiment/c4a88f2f-7111-41d8-af8e-3460a3e84d80/"}]}}, {"id": "source:c6a59e7d788652e0dc5ea023eacc350133bd2b3ef57e0aed68caa614296182ee", "url": "https://finance.yahoo.com/markets/stocks/articles/alcon-inc-alc-q2-2026-210415398.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/alcon-inc-alc-q2-2026-210415398.html", "title": "Alcon Inc (ALC) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Strategic Pivots ...", "content_text": "This article first appeared on GuruFocus. Release Date: August 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Alcon Inc (NYSE:ALC) delivered 7% sales growth in Q2 2026, driven by broad-based strength across both surgical and vision care franchises. Unity VCS equipment sales surged 25% year-over-year, with strong demand and higher-than-expected average selling prices, indicating robust commercial traction. Panoptix Pro IOL adoption exceeded expectations, with nearly all US Panoptix accounts converted and the platform", "date_published": "2026-08-11T21:04:15+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:075b73d293c7e70fcab278c37a05cfa686169b2d4b7e54589715f81be0413b7a", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-scores-major-win-190732274.html", "external_url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-scores-major-win-190732274.html", "title": "Eli Lilly Scores Major Win in Weight-Loss Drug Race", "content_text": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's opportunity beyond injectable drugs such as Zepbound while giving patients a potentially simpler oral option in one of the pharmaceutical industry's fastest-growing markets. Warning! GuruFocus has detected 6 Warning Signs with INTC. Is LLY fairly valued? Test your thesis with our free DCF calculator. ", "date_published": "2026-08-11T19:07:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/2a75d284-1006-47a9-95a6-1b68449f2df1/"}]}}, {"id": "source:bf256c22096898e56876b00217053c9309a895b7f9a71b3f50d1a8662c016134", "url": "https://finance.yahoo.com/markets/stocks/articles/roche-swx-rog-stock-fair-161250128.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/roche-swx-rog-stock-fair-161250128.html", "title": "Roche (SWX:ROG) Stock Fair Value Edges Higher As Analysts Weigh Pipeline Growth", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Roche Holding now sits on a refreshed fair value estimate of CHF 370.31, up from CHF 359.22. This gives you an updated reference point for where analysts see the stock's long term potential. This move lines up with recent research that highlights contrasting views on the company's pipeline, from optimism around giredestrant and 2027 catalysts to more cautious takes on how much upside is already captured in forecasts. Read on to see how these shifting assumptions shape the evolving narrative around Roche Holding and what to watch next. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Roche Holding. What Wall Street Has Been Saying \ud83d\udc02 Bullish Takeaways Morgan Stanley upgraded Roche Holding to Overweight and set a price target of US$63. The firm points to a mix of visible growth and pipeline potential, with giredestrant flagged for possible peak sales of CHF 9b. Several firms, including Truist, RBC Capital, Baird and Jefferies, reference new or expanded partnerships with Roche in their Nurix Therapeutics coverage. These deals are framed as supportive for partner funding and execution, which also underlines external confidence in Roche Holding as a collaborator. \ud83d\udc3b Bearish Takeaways HSBC downgraded Roche to Hold from Buy with an unchanged price target of CHF 365. The firm cites that current pipeline expectations now better reflect potential, which could limit further upside if new data does not reset forecasts. Wells Fargo highlights that, following the bexdeg deal, Nurix has a very early stage wholly owned pipeline. For Roche investors, this points to a model where external partners may carry more early development risk, which can add complexity to how future pipeline value is assessed. Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!SWX:ROP 1-Year Stock Price Chart We've flagged 1 risk for Roche Holding. See which could impact your investment. How This Changes the Fair Value For Roche Holding Fair value estimate adjusted from CHF 359.22 to CHF 370.31 on a discounted cash flow basis. Revenue growth assumption updated from 2.55% to 3.66% in future CHF terms. Net profit margin assumption moved from 25.52% to 26.17% for future revenue. Future P/E multiple revised from 18.35x to 18.09x in the model. Discount rate refined from 3.94% to 3.95% for discounting projected cash flows. Story Continues Never Miss an Update: Follow The Narrative Narratives link Roche Holding's business story to a set of forecasts and a fair value framework, so you can see how clinical data, deals and policy changes fit together. They update as new information arrives, which helps you keep context around each headline. Head over to the Simply Wall St Community and follow the Narrative on Roche Holding to stay up to date on: How a broad late stage pipeline, including up to 19 potential medicine launches and assets such as giredestrant, fenebrutinib and CT-388, could reshape Roche Holding's oncology and metabolic disease portfolio. The role of diagnostics platforms like next generation sequencing, cobas Mass Spec 601 and companion tests in supporting long term demand for Roche's pharmaceutical franchises. Key risks such as China pricing reforms, loss of exclusivity across major drugs, pipeline execution hurdles and currency moves that could challenge margins and earnings if they play out differently to current expectations. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We", "date_published": "2026-08-11T16:12:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "RO", "ROP"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RO", "name": "Roche Holding AG", "sentiment_url": "https://sharemaestro.com/sentiment/30c32009-371c-4d93-ab75-ec2de4550915/"}, {"symbol": "ROP", "name": "Roche Holding AG", "sentiment_url": "https://sharemaestro.com/sentiment/fdac9d6f-d683-44f3-ad28-dfbb55fe934d/"}]}}, {"id": "source:e00ae2dcbb852668f1ce0c32d06654186429b000c62c27e8b0f6e1b8646c663d", "url": "https://finance.yahoo.com/markets/stocks/articles/alcon-stock-jumps-4-tariff-154300390.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/alcon-stock-jumps-4-tariff-154300390.html", "title": "Alcon Stock Jumps 4% as Tariff Relief Lifts Profit Target", "content_text": "This article first appeared on GuruFocus. Alcon (NYSE:ALC), a global eye-care powerhouse, raised its 2026 profitability outlookand investors liked what they saw. The Swiss shares jumped roughly 4% Tuesday as management pushed expected core operating-margin expansion to 90190 basis points at constant currency, up from 70170 basis points. Core diluted EPS growth is now expected to hit 12%15%, versus 10%13% previously. The message is pretty simple: Alcon is growing, margins are getting better, and management thinks there is more room to run. Warning! GuruFocus has detected 6 Warning Sign with TSM", "date_published": "2026-08-11T15:43:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:f53eaa18aedf51372d662341409289f815d56c13511c52603faa6fe7cd092351", "url": "https://finance.yahoo.com/healthcare/articles/lilly-takes-weight-loss-pill-151241058.html", "external_url": "https://finance.yahoo.com/healthcare/articles/lilly-takes-weight-loss-pill-151241058.html", "title": "Lilly Takes Its Weight-Loss Pill Battle Overseas", "content_text": "This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's Wegovy tablet in one of Europe's biggest drug marketplaces.Foundayo will initially be provided by private prescription. Availability will be wider via the U.K.'s National Health Service, subject to a review of cost efficiency.Lilly is banking on convenience to help it catch up with Novo. You can take Foundayo", "date_published": "2026-08-11T15:12:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/2a75d284-1006-47a9-95a6-1b68449f2df1/"}]}}, {"id": "source:8bff636033b9a135246cd57fe0761b00a58cc843c827483397f6e1377ad897ea", "url": "https://finance.yahoo.com/markets/stocks/articles/tecan-group-ag-tchbf-h1-150026054.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/tecan-group-ag-tchbf-h1-150026054.html", "title": "Tecan Group AG (TCHBF) (H1 2026) Earnings Call Highlights: Strategic Progress and Market ...", "content_text": "This article first appeared on GuruFocus. Release Date: August 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Tecan Group AG (TCHBF) delivered solid above-market growth in both segments, with group sales up 3.4% in local currencies and order entry up 3%, maintaining a book-to-bill ratio above 1. The company's adjusted EBITDA margin improved slightly to 15.1%, despite significant headwinds from FX and tariffs, with underlying profitability up 108 basis points due to higher volumes, favorable product mix, and initial ", "date_published": "2026-08-11T15:00:26+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TECN", "BION"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TECN", "name": "Tecan Group AG", "sentiment_url": "https://sharemaestro.com/sentiment/c4a88f2f-7111-41d8-af8e-3460a3e84d80/"}, {"symbol": "BION", "name": "BB Biotech AG", "sentiment_url": "https://sharemaestro.com/sentiment/d5faa5b5-21aa-4183-97e6-5c9badcfcdaa/"}]}}, {"id": "source:307c68c8377bcf013ad783581ce907b734df56f45e0558685346ed0bf0510ade", "url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "external_url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "title": "REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?", "content_text": "The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index during this time. REGN's robust rally has been driven by better-than-expected quarterly results, which can be attributed to robust demand for Eylea HD (higher dose of Eylea) and higher profit-sharing from Dupixent that helped the company mitigate the decline in Eylea sales. REGN Outperforms Industry, Sector and S&P 500 IndexZacks Investment Research Image Source: Zacks Investment Research Against this backdrop, a closer evaluation of the company's strengths and weaknesses can help assess its attractiveness as an investment opportunity. REGN's Eylea HD Gains Traction as Eylea Sales Decline While lead drug Eylea continues to face headwinds, Eylea HD is gaining traction, supported by steady label expansions. Eylea is an anti-VEGF therapy approved across multiple ophthalmology indications. Declining sales of this drug continue to pressure the company's overall revenues. Competitive pressure has intensified, particularly from Roche's RHHBY Vabysmo, which targets both angiopoietin-2 (Ang-2) and VEGF-A pathways and has gained meaningful traction in the retinal disease market. RHHBY's Vabysmo sales grew 8% to CHF 2 billion in the first half of 2026 on continued global growth. To combat the decline in Eylea sales, Regeneron introduced Eylea HD, a higher-dose formulation of Eylea designed to improve durability and extend dosing intervals, Eylea HD sales in the United States surged 52% year over year to $596 million in the second quarter of 2026, driven by strong uptake following recent FDA label expansions and growing physician confidence in its differentiated profile and flexible dosing regimen. In April 2026, the FDA approved the extension of dosing intervals for Eylea HD to up to every 20 weeks (5 months) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) following a year of successful response based on visual and anatomic outcomes. The regulatory body had earlier approved Eylea HD for the treatment of macular edema following retinal vein occlusion (RVO), with dosing of up to once every eight weeks after an initial monthly dosing phase. The FDA also approved a monthly dosing option for certain patients who may benefit from resuming this dosing schedule across all currently approved indications, including wet age-related macular degeneration, DME, diabetic retinopathy and RVO. Story Continues Eylea and Eylea HD were co-developed with Bayer BAYRY. Regeneron records net product sales in the United States, while Bayer records sales outside the country. It expects a further decline in Eylea sales in the second half of 2026 due to ongoing conversion to Eylea HD and increasing competition as multiple biosimilar versions enter the U.S. market. Strong Dupixent Sales Fuel REGN Profits REGN's top line also comprises its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi records global net product sales of Dupixent. Dupixent continues to deliver strong growth across key indications, including atopic dermatitis, asthma, nasal polyps and eosinophilic esophagitis, while newer uses such as COPD, chronic spontaneous urticaria, bullous pemphigoid and allergic fungal rhinosinusitis are gaining traction. Ongoing label expansions for Dupixent remain a key contributor to revenue visibility and profitability. Regeneron Strengthens Its Oncology Portfolio Regeneron's oncology franchise is anchored by its PD-1 inhibitor Libtayo (cemiplimab-rwlc), which is approved for use in certain patients with advanced basal cell carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC) and advanced non-small cell lung cancer (NSCLC). Libtayo sales continue to be robust, driven by strength across non-melanoma skin cancers and NSCL", "date_published": "2026-08-11T14:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "RO"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "RO", "name": "Roche Holding AG", "sentiment_url": "https://sharemaestro.com/sentiment/30c32009-371c-4d93-ab75-ec2de4550915/"}]}}, {"id": "source:b73086cee8595e9c6565726d1d9bba756e56285268fc7a9f76283c912bb898cf", "url": "https://finance.yahoo.com/markets/stocks/articles/alcons-q2-earnings-revenues-surpass-131700423.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/alcons-q2-earnings-revenues-surpass-131700423.html", "title": "Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs", "content_text": "Alcon Inc. ALC delivered second-quarter 2026 core earnings per share (EPS) of 84 cents, up 10.5% year over year. The figure beat the Zacks Consensus Estimate by 9.09%. The company reports core results based on non-IFRS (International Financial Reporting Standards) measures. In the second quarter, EPS was nil compared with 35 cents in the year-ago quarter. Net sales of $2.78 billion rose 8% and topped the consensus estimate by 0.58%. Following the announcement, ALC's stock price rose 3.2% during the after-market trading session yesterday. Segmental Breakup of Alcon's Q2 Revenues Alcon's Surgica", "date_published": "2026-08-11T13:17:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:97f6e7dd7967fab0fced2a61373648d8b2954f601c1b248325bdc8700e25ec1f", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-company-lly-vs-124416743.html", "external_url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-company-lly-vs-124416743.html", "title": "Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?", "content_text": "The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns for Zepbound and Mounjaro. While both pharmaceutical giants continue to deliver massive top-line growth, a look at their underlying fundamentals shows that one company is clearly pulling ahead in execution, clinical trial", "date_published": "2026-08-11T12:44:16+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/2a75d284-1006-47a9-95a6-1b68449f2df1/"}]}}, {"id": "source:cf0ecb46e6880668dbb804c6b9816e5f7d4dcfe55cf73dbe52d91f7fc143d3f5", "url": "https://finance.yahoo.com/markets/world-indices/articles/earnings-nudge-european-bourses-higher-114143387.html", "external_url": "https://finance.yahoo.com/markets/world-indices/articles/earnings-nudge-european-bourses-higher-114143387.html", "title": "Earnings Nudge European Bourses Higher Midday", "content_text": "European bourses tracked modestly higher midday Tuesday as traders weighed corporate earnings result PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-11T11:41:43+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:c527c5b034b205af0aa5b4aa07cc40dbef68a77e9ff5b10584ff0e5a67ac1acf", "url": "https://finance.yahoo.com/healthcare/articles/alcon-raises-2026-earnings-growth-112507026.html", "external_url": "https://finance.yahoo.com/healthcare/articles/alcon-raises-2026-earnings-growth-112507026.html", "title": "Alcon raises 2026 earnings growth outlook on positive Q2 results", "content_text": "Alcon has reported Q2 revenues of around $2.8bn, indicative of an 8% uptick year-over-year (YoY), prompting it to revise its 2026 outlook. The Swiss eyecare specialist now expects 2026 earnings growth to land in the 12% to 15% per diluted share range, up from 10% to 13% previously. Alcon is maintaining its YoY sales growth outlook within the 5% to 7% range. The lion's share of Alcon's profits came from its surgical segment at around $1.6bn, indicative of an 8% uptick YoY, with vision care in second place with sales of around $1.2bn corresponding to an increase of 8% compared to the same quarte", "date_published": "2026-08-11T11:25:07+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:b5fb12adf12b32b3e508e65101cf9d7e68458d57d40359dcff74ad48d03475b2", "url": "https://finance.yahoo.com/healthcare/articles/veeva-vault-crm-selected-eli-110300980.html", "external_url": "https://finance.yahoo.com/healthcare/articles/veeva-vault-crm-selected-eli-110300980.html", "title": "Veeva Vault CRM Selected by Eli Lilly and Company", "content_text": "PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Eli Lilly and Company Vault CRM is part of the Vault CRM Suite of applications that provides the technology foundation for agentic commercial, the new commercial model that leverages AI to get the right medicines to more patients. \"We are excited to expand our strategic work with Veeva by moving to Vault CRM,\" said Giuseppe Firenze, senior vice president, U.S. HCP and field engagement hub at Lilly. ", "date_published": "2026-08-11T11:03:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "LLY"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/2a75d284-1006-47a9-95a6-1b68449f2df1/"}]}}, {"id": "source:a680b8f5b4ee5ebeb971df18b00463673f795296a5ca440b5fb5afad98084bed", "url": "https://finance.yahoo.com/markets/stocks/articles/alcon-raises-profit-guidance-cuts-073049334.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/alcon-raises-profit-guidance-cuts-073049334.html", "title": "Alcon rises on profit guidance hike, lowered tariff impact estimate", "content_text": "Investing.com -- Alcon lifted its full-year profit guidance late Monday and lowered its estimate for the annual tariff impact to $40 million to $90 million, from a prior range of $100 million to $150 million, factoring in an anticipated refund of around $60 million from the U.S. government. The U.S. accounted for 45% of Alcon's net sales in the first half of the year, and most of the company's major production facilities are located there. Shares rose more than 3% by 08:24 GMT. The Swiss-American eye care company now expects its core operating profit margin to rise 90 to 190 basis points in 20", "date_published": "2026-08-11T07:30:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:c45360021516e02d8c9c4895915f3ef1d38f716d5c19dcdde5ee0daac3045e5c", "url": "https://www.nasdaq.com/articles/eli-lillys-foundayo-wins-uk-approval", "external_url": "https://www.nasdaq.com/articles/eli-lillys-foundayo-wins-uk-approval", "title": "Eli Lilly's Foundayo Wins UK Approval", "content_text": "(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory Agency (MHRA) on August 10, 2026, follows the U.S. FDA's approval in April 2026, positioning Foundayo as a key entrant in the competitive obesity and diabetes market. Foundayo (orforglipron) is a small-molecule GLP-1 receptor agonist designed for convenient daily use without food or water restrictions. Clinical data", "date_published": "2026-08-11T07:30:37+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/2a75d284-1006-47a9-95a6-1b68449f2df1/"}]}}, {"id": "source:288b5de31c23624268113636022f03a14813811a8fbae00a227b77cda6f0b41c", "url": "https://finance.yahoo.com/healthcare/articles/galderma-receives-european-union-approval-050000475.html", "external_url": "https://finance.yahoo.com/healthcare/articles/galderma-receives-european-union-approval-050000475.html", "title": "Galderma Receives European Union Approval for Restylane\u00ae Shaype\u2122: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping", "content_text": "Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1 Restylane Shaype is the firmest HA gel available, powered by new NASHA HD\u2122 technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3 It is the latest addition to the innovative Restylane portfolio \u2013 the world's most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4 ZUG, Switzerland, August 11, 20", "date_published": "2026-08-11T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "GALD"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GALD", "name": "GALDERMA GROUP N", "sentiment_url": "https://sharemaestro.com/sentiment/59e98105-9bab-416f-8854-94c75e42afe2/"}]}}, {"id": "source:b1d649f96dfc228ae3253969f0ea7e8c9065170c8714dd4049f8b4cab3ca9aff", "url": "https://finance.yahoo.com/healthcare/articles/tecan-reports-growth-3-4-050000057.html", "external_url": "https://finance.yahoo.com/healthcare/articles/tecan-reports-growth-3-4-050000057.html", "title": "Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed", "content_text": "Tecan Group AG Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed Financial highlights \u2013 first half of 2026 Sales of CHF 427.5 million, up 3.4% in local currencies; with growth in both Life Sciences Business (+3.1% LC) and Partnering Business (+3.6% LC) Order entry up 3.0% in local currencies, book-to-bill ratio remaining above 1 in both segments Adjusted EBITDA margin at 15.1%, with underlying profitability improvements of 180 ", "date_published": "2026-08-11T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TECN"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TECN", "name": "Tecan Group AG", "sentiment_url": "https://sharemaestro.com/sentiment/c4a88f2f-7111-41d8-af8e-3460a3e84d80/"}]}}, {"id": "source:de069f299054c9af8de14aa74875047da560b3bfada47a92f9785489980dde6e", "url": "https://finance.yahoo.com/markets/stocks/articles/alcon-swx-alc-why-latest-031919363.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/alcon-swx-alc-why-latest-031919363.html", "title": "Alcon (SWX:ALC), Why Is Its Latest Update Drawing Attention?", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Alcon's latest earnings matter for shareholders Alcon (SWX:ALC) has just reported second quarter 2026 results that combine higher sales with lower profits, giving investors fresh numbers to reassess how the eye care specialist is currently performing. The company reported quarterly sales of US$2.78b and revenue of US$2.82b, compared with US$2.58b and US$2.60b a year earlier, while net income for the first half of 2026 declined to US$189m from US$526m. See our latest analy", "date_published": "2026-08-11T03:19:19+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:e654c67e11b2c5529ac081053a41daaa4de67a9183534dbc1a947b006af0d655", "url": "https://finance.yahoo.com/markets/stocks/articles/eli-lilly-lly-stock-gets-232051909.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/eli-lilly-lly-stock-gets-232051909.html", "title": "Eli Lilly (LLY) Stock Gets Fair Value Bump After GLP 1 Driven Analyst Revisions", "content_text": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eli Lilly's updated fair value price target has shifted from US$1,270.37 to US$1,297.31, giving investors a fresh reference point for how analysts are framing the stock today. Much of this reset is tied to recent Street commentary that focuses on incretin and GLP-1 therapies, Q2 results, and the potential of assets like Mounjaro, Zepbound, retatrutide and Foundayo. As you read on, you will see how to track these moving parts and keep up with the evolving Eli Lilly narrative. Stay ", "date_published": "2026-08-10T23:20:51+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "LLY"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/2a75d284-1006-47a9-95a6-1b68449f2df1/"}]}}, {"id": "source:99a501eedeb3958ebe6a4d1351adb2e9a43c8bc2f34e87f9aa19ae7d64103286", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-medtronic-healthcare-223657921.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-medtronic-healthcare-223657921.html", "title": "Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?", "content_text": "Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts' average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The healthcare giant raised its full-year outlook and said it remains on track to generate more than $100 billion in annual revenue for the first time in its 140-year history. Medtronic (NYSE:MDT), meanwhile, ended fiscal 2026 with its fastest annual revenue growth in a decade. Several newer products ar", "date_published": "2026-08-10T22:36:57+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "JNJ"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "JOHNSON&JOHNSON", "sentiment_url": "https://sharemaestro.com/sentiment/64c0807a-7d61-415c-b23f-0e2f1970f21f/"}]}}, {"id": "source:b684a58c5c959ed66be0519a941f51c99f5950532c86425b3e8ce59d4b175d42", "url": "https://www.nasdaq.com/articles/why-eli-lilly-topped-market-today", "external_url": "https://www.nasdaq.com/articles/why-eli-lilly-topped-market-today", "title": "Why Eli Lilly Topped the Market Today", "content_text": "Key Points This market has a population of almost 60 million. While the drug isn't the first of its type to be sold in that country, it will have Lilly's considerable marketing power behind it.10 stocks we like better than Eli Lilly \u203a Eli Lilly(NYSE: LLY) had a fine start to the trading week. On Monday, its stock rose by almost 4% on news that a key European regulator had approved one of its star medications. That also provided plenty of optimism for these types of drugs, which have been hotly popular for years now. The popular pill The product in question is Lilly's Foundayo, its first weight", "date_published": "2026-08-10T22:13:52+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/2a75d284-1006-47a9-95a6-1b68449f2df1/"}]}}, {"id": "source:10fac4cddab8c85ee9d8aa174c2663bdac4e7bd3d18f994f7d41adede7c5fcc9", "url": "https://finance.yahoo.com/markets/stocks/articles/alcon-alc-q2-earnings-taking-220001451.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/alcon-alc-q2-earnings-taking-220001451.html", "title": "Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates", "content_text": "Alcon (ALC) reported $2.78 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 8%. EPS of $0.84 for the same period compares to $0.76 a year ago. The reported revenue represents a surprise of +0.58% over the Zacks Consensus Estimate of $2.77 billion. With the consensus EPS estimate being $0.77, the EPS surprise was +9.09%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better i", "date_published": "2026-08-10T22:00:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:3d6b4a880af04ea7f87fdee32007872f1d1bf19cac3e941214eb4dd63c23c322", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxQOWpTb0hVYlEtNkZ2SzJndUgxbGtDRUVKU2g5ZXQtUlNxY1VBbmZwUVduU3l0ZUNaWWcyLTJlcDNtYjNZQm15VnRaRFY0eXJxNVpfU0hBVGo2UXBCT2hyWUViOV9oeXo5b2tsRlRna05FZWJIRFF3cHl6QUdXZlhTeERxOTRjYlpSOXFaamwxWUctWGxGbkxJTHJfZm5GWENkYkd2dlBmMGFRaGtBM2hoWHVBT1ZaNnMwZkVMbHZfTUdRdnNweUVROXBvaV9HVkJsZC0ySThXaDFEVU5DcHdCTENNNE9EN3R5dWVhaVJKUXIxeFc1N2hfcQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxQOWpTb0hVYlEtNkZ2SzJndUgxbGtDRUVKU2g5ZXQtUlNxY1VBbmZwUVduU3l0ZUNaWWcyLTJlcDNtYjNZQm15VnRaRFY0eXJxNVpfU0hBVGo2UXBCT2hyWUViOV9oeXo5b2tsRlRna05FZWJIRFF3cHl6QUdXZlhTeERxOTRjYlpSOXFaamwxWUctWGxGbkxJTHJfZm5GWENkYkd2dlBmMGFRaGtBM2hoWHVBT1ZaNnMwZkVMbHZfTUdRdnNweUVROXBvaV9HVkJsZC0ySThXaDFEVU5DcHdCTENNNE9EN3R5dWVhaVJKUXIxeFc1N2hfcQ?oc=5", "title": "Alcon Inc. gibt Ergebnisprognose f\u00fcr den im Juli 2026 endenden Monat ab; best\u00e4tigt Ergebnisprognose f\u00fcr das Gesamtjahr 2026", "content_text": "Alcon Inc. gibt Ergebnisprognose f\u00fcr den im Juli 2026 endenden Monat ab; best\u00e4tigt Ergebnisprognose f\u00fcr das Gesamtjahr 2026", "date_published": "2026-08-10T20:30:00+00:00", "authors": [{"name": "MarketScreener Schweiz"}], "tags": ["Market update", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:2ee8dfc8e83b3660b9509bfc52962105fb4366c13cb70ad08b2caab8168db32e", "url": "https://finance.yahoo.com/healthcare/articles/product-launches-strong-commercial-execution-203000250.html", "external_url": "https://finance.yahoo.com/healthcare/articles/product-launches-strong-commercial-execution-203000250.html", "title": "New Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth", "content_text": "Second-quarter 2026 sales of $2.8 billion, up 8%on a reported basis, or up 7% constant currency1 (cc), versus second-quarter 2025 Returned $538 million to shareholders through dividends and share repurchases on a year-to-date basis Updated full-year guidance - raised core operating margin and core diluted EPS growth Ad Hoc Announcement Pursuant to Art. 53 LR GENEVA, August 10, 2026--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2026. For the second quarter of 2026, sales ", "date_published": "2026-08-10T20:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}, {"id": "source:973aaf939467d5b41ccdd4cf57467a13f413c28d4c8bda050cabf518ef3a488f", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-stock-rises-2-193507373.html", "external_url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-stock-rises-2-193507373.html", "title": "Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill", "content_text": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) just added another weapon to its obesity arsenal. The pharmaceutical giant received British authorization for Foundayo on Monday, making the U.K. the first European country to clear the once-daily orforglipron tablet for weight management and type 2 diabetes. Lilly shares rose approximately 2.1% in regular trading. The appeal is easy to understand: no injection. Foundayo targets GLP-1 while giving patients an oral alternative to Lilly's blockbuster Mounjaro and Zepbound. The pill entered the U.S. market in April and generated $98 m", "date_published": "2026-08-10T19:35:07+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/2a75d284-1006-47a9-95a6-1b68449f2df1/"}]}}, {"id": "source:1f3a1d2d0e41f5a6089112952037dac0c453a7c78b4d75fbfa04ceabaf7c7c68", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-challenge-intuitive-124242559.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-challenge-intuitive-124242559.html", "title": "Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava\u2019s FDA Approval?", "content_text": "Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon relationships, and a rapidly expanding da Vinci 5 platform. The question for investors is not whether OTTAVA can become a viable product, but whether Johnson & Johnson (NYSE:JNJ) can convert its differ", "date_published": "2026-08-10T12:42:42+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "JNJ"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "JOHNSON&JOHNSON", "sentiment_url": "https://sharemaestro.com/sentiment/64c0807a-7d61-415c-b23f-0e2f1970f21f/"}]}}, {"id": "source:3c47b8ef3ab797724be0ddfe5eb202d239caee7fc93025f9971b079f4bb6097c", "url": "https://finance.yahoo.com/healthcare/articles/chemometec-enters-collaboration-agreement-roche-103200914.html", "external_url": "https://finance.yahoo.com/healthcare/articles/chemometec-enters-collaboration-agreement-roche-103200914.html", "title": "ChemoMetec enters collaboration agreement with Roche Diagnostics", "content_text": "Chemometec A/S ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties' solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today entered a collaboration agreement. The agreement covers the development of a connection kit between the Roche-owned Cedex\u00ae Bio Analyzer and the ChemoMetec-owned Xcytomatic\u00ae 30 (XM30) cell counting analyzer, as well as aspects of the subsequent commercialization of the connectivity solution. Roche will be responsible for the design of the connection kit and for the verification and validation activities. The connection kit is intended to result in a connectivity solution on hard- and software level, establishing a flawless integration and connection between the ChemoMetec XM30 and the Roche Cedex\u00ae Bio Analyzer. The two parties commit to a joint go-to-market strategy to actively co-promote the combined solution to current and prospective customers, but each party will remain the sole seller of its respective instrument and analyzers. Additional Information Martin Helbo Behrens, CEO Tel.: (+45) 81 10 06 80 About ChemoMetec A/S ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec's customers include some of the world's leading pharmaceutical companies. ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com. Attachment Announcement 311 - Roche Collaboration Agreement View Comments", "date_published": "2026-08-10T10:32:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "RO", "ROP"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RO", "name": "Roche Holding AG", "sentiment_url": "https://sharemaestro.com/sentiment/30c32009-371c-4d93-ab75-ec2de4550915/"}, {"symbol": "ROP", "name": "Roche Holding AG", "sentiment_url": "https://sharemaestro.com/sentiment/fdac9d6f-d683-44f3-ad28-dfbb55fe934d/"}]}}, {"id": "source:1b6c75608c039ae482a7ea81916f849cb9c4e0afc0e1f524284fa77b627dde47", "url": "https://finance.yahoo.com/markets/stocks/articles/storebrand-europe-index-announcement-prospectus-072500902.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/storebrand-europe-index-announcement-prospectus-072500902.html", "title": "Storebrand Europe Index - announcement of prospectus", "content_text": "Storebrand Asset Management AS Lysaker, 10 August 2026 Storebrand hereby announces the Prospectus with Articles of Association Appendix to the Prospectus (\"till\u00e6g\" relevant to Danish investors) for Storebrand Europe Index, an index aware equity fund. The fund has been accepted for listing at Nasdaq Copenhagen and is scheduled for trading on Wednesday 12 August 2026. At end of business on 7 August 2026 the fund had the following diversification characteristics for the shareclass to be listed, Storebrand Europe Index A5 \u2013 ISIN NO0013711408: Total net assets (\"Formue\"): DKK 135.524,10 Outstanding", "date_published": "2026-08-10T07:25:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "BION"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BION", "name": "BB Biotech AG", "sentiment_url": "https://sharemaestro.com/sentiment/d5faa5b5-21aa-4183-97e6-5c9badcfcdaa/"}]}}, {"id": "source:c20b0243a7a167658a7d7be160907b68671f52652be55c611c118b9ae1841042", "url": "https://finance.yahoo.com/m/bd14b29c-18a2-3bb0-930e-e50923390400/nvidia%2C-eli-lilly%2C-and-disney.html", "external_url": "https://finance.yahoo.com/m/bd14b29c-18a2-3bb0-930e-e50923390400/nvidia%2C-eli-lilly%2C-and-disney.html", "title": "Nvidia, Eli Lilly, and Disney Show It\u2019s Time to Back the Top Dogs", "content_text": "Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading", "date_published": "2026-08-10T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "LLY"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/2a75d284-1006-47a9-95a6-1b68449f2df1/"}]}}, {"id": "source:3cb3a0ab66137cd9783789ec1f1f7b34aafefa56a0f7be0ac7efde740bf98df6", "url": "https://finance.yahoo.com/healthcare/articles/lineage-cell-therapeutics-q2-earnings-190402390.html", "external_url": "https://finance.yahoo.com/healthcare/articles/lineage-cell-therapeutics-q2-earnings-190402390.html", "title": "Lineage Cell Therapeutics Q2 Earnings Call Highlights", "content_text": "Key Points Interested in Lineage Cell Therapeutics, Inc.? Here are five stocks we like better. Pipeline progress: Lineage advanced preclinical programs in corneal disease, Type 1 diabetes and hearing loss, while Roche and Genentech continued optimizing surgical delivery for the lead OpRegen retinal therapy. Clinical developments: The OPC1 DOSED study has treated two chronic spinal-cord-injury patients without unexpected safety issues, though the study is not designed to measure efficacy. OpRegen remains eligible for up to $615 million in development and commercial milestones plus tiered double-digit royalties. Financial position: Lineage ended the quarter with $50.8 million in cash and marketable securities, extending its expected runway into Q3 2028. Revenue fell to $1.1 million, but net income reached $1.5 million, primarily due to a non-cash warrant-liability gain. Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimization work for its lead OpRegen program. Chief Executive Officer Brian Culley said the company's strategy, which it calls \"Lineage 3.0,\" centers on using its AlloSCOPE manufacturing platform to develop allogeneic, or off-the-shelf, cell therapies that can be produced consistently at scale. Culley said the company aims to target indications where small initial trials could generate meaningful treatment signals and where Lineage can retain improved economics through internal development or partnerships. AlloSCOPE Manufacturing Focus \u2192 No Hangover: Revisiting Microsoft One Week After Earnings Culley said Lineage has established a two-tier current good manufacturing practice banking and production system that it believes can produce millions of vials of a product candidate. Material from those banks has been cleared by the FDA and used in the OpRegen clinical trial, he said. The company believes the platform can support production costs in the hundreds of dollars per dose, compared with potentially much higher costs for autologous therapies. Culley emphasized that cell-therapy manufacturing requires reproducibility, purity, potency and scalability, and said changes to a production process after early clinical trials can create regulatory and comparability risks. \u2192 MarketBeat Week in Review \u2013 08/03 - 08/07 During the question-and-answer session, Culley declined to provide more detailed information on the vessel sizes used in the company's Type 1 diabetes manufacturing work, citing the proprietary nature of the process. He said Lineage's approach is to establish a scalable manufacturing process early rather than modify it later after clinical data are obtained. Story Continues Preclinical Pipeline Updates Lineage's wholly owned COR1 program is being developed as a corneal endothelial cell therapy for Fuchs' dystrophy and other corneal endothelial diseases. The company began evaluating the program in the second quarter of 2025 and initiated laboratory work in the third quarter of that year. \u2192 Why the Landlord of the AI Boom Could Outlast the Chipmakers According to Culley, Lineage has applied its AlloSCOPE 5D technology to expand precursor cells in bioreactors and differentiate them into corneal endothelial cells. Preclinical in vivo testing is expected to begin imminently, with initial internal animal data targeted by year-end. The company plans to evaluate whether its cells perform at least as well as cadaver-derived cells in established efficacy models. Culley said the program addresses supply and shelf-life limitations in donor-derived corneal transplants. He cited an estimate of one donor for every 70 diseased eyes globally and noted that donor-derived material must be used promptly rather than cryopreserved. In response to an analyst question, Culley said the existing cl", "date_published": "2026-08-09T19:04:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ROP"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ROP", "name": "Roche Holding AG", "sentiment_url": "https://sharemaestro.com/sentiment/fdac9d6f-d683-44f3-ad28-dfbb55fe934d/"}]}}, {"id": "source:87a1fc6b527bdca11053464b79d729c447de8f314f33673826d4f20bc8906505", "url": "https://www.nasdaq.com/articles/johnson-johnson-has-increased-its-dividend-64-consecutive-years-heres-how-much-10000", "external_url": "https://www.nasdaq.com/articles/johnson-johnson-has-increased-its-dividend-64-consecutive-years-heres-how-much-10000", "title": "Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.", "content_text": "Key Points Few companies have a longer track record of uninterrupted dividend growth. This streak is likely to be prolonged well into the foreseeable future. While still an income stock, Johnson & Johnson is also being priced somewhat like a growth stock.10 stocks we like better than Johnson & Johnson \u203a It's certainly not the market's most exciting stock, and not its highest-yielding one either. If you want reliable dividend growth, though, you'd be hard-pressed to find a better option than drugmaker Johnson & Johnson(NYSE: JNJ). In fact, after 64 straight years of annual dividend increases --", "date_published": "2026-08-09T13:35:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Deals and strategy", "JNJ"], "_sharemaestro": {"country": "Switzerland", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "JOHNSON&JOHNSON", "sentiment_url": "https://sharemaestro.com/sentiment/64c0807a-7d61-415c-b23f-0e2f1970f21f/"}]}}, {"id": "source:b34e1af58234f6b7dfa4cba07d4f7c14f25e85cad001b777845b73e7830cf0f0", "url": "https://seekingalpha.com/news/4629639-earnings-week-ahead-smci-csco-jd-plug-and-more?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4629639-earnings-week-ahead-smci-csco-jd-plug-and-more?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Earnings Week Ahead: SMCI, CSCO, JD, PLUG, and more", "content_text": "[Business Person Reviewing Quarterly Report During Meeting in Office Setting] The second full week of August features a diverse earnings slate spanning AI infrastructure, semiconductors, space technology, healthcare, financials, and consumer names, with Super Micro Computer (SMCI [https://seekingalpha.com/symbol/SMCI]), Nebius (NBIS [https://seekingalpha.com/symbol/NBIS]), Cisco Systems (CSCO [https://seekingalpha.com/symbol/CSCO]), CoreWeave (CRWV [https://seekingalpha.com/symbol/CRWV]), Applied Materials (AMAT [https://seekingalpha.com/symbol/AMAT]), and Lumentum (LITE [https://seekingalpha.", "date_published": "2026-08-09T12:07:00+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "Switzerland", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/446962d8-e46c-461d-bbe6-40ebea843510/"}]}}]}